文献速递肿瘤 PET/CT

基于代谢生物标志物的黑色素瘤BRAFV600突变关联与预测

Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma.
PubMed 文献 · J Nucl Med · 2019-09-03

结果显示BRAFV600突变与常规PET特征无关联,影像组学特征预测价值低(AUC=0.62),且特征选择方法影响模型性能。

要点

  • 常规PET特征(SUVmax等)与BRAFV600突变状态无显著关联。
  • 影像组学特征预测BRAFV600突变的AUC为0.62,价值有限。
  • 特征选择方法影响预测模型性能,需规范方法学。

核心结论

  • BRAFV600突变状态与常规PET特征无关联,影像组学特征预测价值低(AUC=0.62)。
  • 仅基于18F-FDG PET/CT检测黑色素瘤BRAFV600状态尚不提供临床相关信息。

研究设计与样本

  • 按突变状态分为BRAFV600组(35例,100个病灶)和BRAF野生型组(35例,79个病灶)。
  • 采用6种特征选择方法,构建10折交叉验证预测模型,以AUC评估性能。

主要发现

  • 预测BRAFV600突变的AUC范围为0.54至0.62,受特征选择方法影响。
  • 最佳AUC由基于文献的特征选择、惩罚二项逻辑回归模型和随机森林模型获得。
  • BRAFV600组与BRAF野生型组在常规PET特征上无显著差异,常规PET特征无预测价值。

关键数值与推荐

  • 预测BRAFV600突变的AUC最高为0.62(影像组学特征)。
  • 常规PET特征(SUVmax、SUVmean、SUVpeak、TLG)两组间无显著差异。

临床怎么用

  • 目前不应仅依据18F-FDG PET/CT特征判断黑色素瘤BRAFV600突变状态。
  • 影像组学特征预测价值低,尚不足以替代基因检测。

局限性

  • 影像组学特征预测价值低(AUC=0.62),未达到临床可用水平。
  • 特征选择方法影响模型性能,结果可能受方法学选择影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to associate and predict B-rapidly accelerated fibrosarcoma valine 600 (BRAFV600) mutation status with both conventional and radiomics 18F-FDG PET/CT features, while exploring several methods of feature selection in melanoma radiomics. Methods: Seventy unresectable stage III-IV melanoma patients who underwent a baseline 18F-FDG PET/CT scan were identified. Patients were assigned to the BRAFV600 group or BRAF wild-type group according to mutational status. 18F-FDG uptake quantification was performed by semiautomatic lesion delineation. Four hundred eighty radiomics features and 4 conventional PET features (SUVmax, SUVmean, SUVpeak, and total lesion glycolysis) were extracted per lesion. Six different methods of feature selection were implemented, and 10-fold cross-validated predictive models were built for each. Model performances were evaluated with areas under the curve (AUCs) for the receiver operating characteristic curves. Results: Thirty-five BRAFV600 mutated patients (100 lesions) and 35 BRAF wild-type patients (79 lesions) were analyzed. AUCs predicting the BRAFV600 mutation varied from 0.54 to 0.62 and were susceptible to feature selection method. The best AUCs were achieved by feature selection based on literature, a penalized binary logistic regression model, and random forest model. No significant difference was found between the BRAFV600 and BRAF wild-type group in conventional PET features or predictive value. Conclusion: BRAFV600 mutation status is not associated with, nor can it be predicted with, conventional PET features, whereas radiomics features were of low predictive value (AUC = 0.62). We showed feature selection methods to influence predictive model performance, describing and evaluating 6 unique methods. Detecting BRAFV600 status in melanoma based on 18F-FDG PET/CT alone does not yet provide clinically relevant knowledge.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Saadani H, van der Hiel B, Aalbersberg EA, et al. Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma. J Nucl Med. 2019. PMID: 31481581. doi:10.2967/jnumed.119.228312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。